

Subscribe to  
Bioshares  
\$550/  
24 issues

More details can be found  
on the back page

Companies covered: 1AD, AVR, CGS,  
DXB

	Bioshares Portfolio
Year 1 (May '01 - May '02)	21.2%
Year 2 (May '02 - May '03)	-9.4%
Year 3 (May '03 - May '04)	70.6%
Year 4 (May '04 - May '05)	-16.3%
Year 5 (May '05 - May '06)	77.8%
Year 6 (May '06 - May '07)	17.4%
Year 7 (May '07 - May '08)	-35.8%
Year 8 (May '08 - May '09)	-7.4%
Year 9 (May '09 - May '10)	50.2%
Year 10 (May '10 - May '11)	45.4%
Year 11 (May '11 - May '12)	-18.0%
Year 12 (May '12 - May '13)	3.1%
Year 13 (May '13 - May '14)	26.6%
Year 14 (May '14 - May '15)	23.0%
Year 15 (May '15 - May '16)	33.0%
Year 16 (May '16 - May '17)	16.8%
Year 17 (May '17 - May '18)	-7.1%
Year 18 (May '18 - May '19)	-2.3%
Year 19 (May '19 - May '20)	39.5%
Year 20 (May '20 - May '21)	86.8%
Year 21 (May '21 - May '22)	-15.6%
Year 22 (May '22 - Current)	-2.4%
Cumulative Gain	1576%
Av. Annual gain (21 yrs)	19.0%

Bioshares is published by Blake Industry & Market Analysis Pty Ltd.  
ACN 085 334 292  
PO Box 447  
Flinders Lane Vic 8009  
AFS Licence No. 258032

**Mark Pachacz - Editor/Analyst**  
Email: mark[at]bioshares.com.au  
Ph: 0403 850 425

Edition Number 930 (16 December 2022)

Copyright 2021 Blake Industry and Market Analysis Pty Ltd. ALL RIGHTS RESERVED.  
Secondary electronic transmission, photocopying, reproduction or quotation is strictly prohibited without written consent of the publisher.

# Bioshares

16 December 2022  
Edition 930

*Delivering independent investment research to investors on Australian  
biotech, pharma and healthcare companies*

*Extract from Bioshares –*

## **Adalta Returns to IV Formulation for AD-214**

Last year novel antibody company Adalta (1AD: \$0.044) announced that it would be moving to develop an inhaled formulation of its lead drug candidate, AD-214. This followed preclinical studies that showed high accumulation of the compound in the liver, although no liver toxicity was observed in patients in the Phase I study.

However, it has decided to return to an intravenous delivered version of the compound, which was re-engineered in 2018 (from AD-114) to provide a longer half-life for less frequent administration.

There were three key reasons the company has decided to move back to developing the intravenous formulation of AD-214.

Over the last 18 months Adalta has developed an inhaled version of AD-214, however this could not be successfully tested in a mouse model of lung disease. In this time, data was published on the potential efficacy of AD-214 in kidney disease, for which an inhaled therapy would not be suitable. And the duration of receptor occupancy has been found to be longer than earlier expected, with a three day (71 hours) elimination half-life in the blood stream.

With the now longer than expected binding of the target, an intravenous version could be delivered to patients every one to two weeks. (Studies have shown that 90% target inhibition is sustained at the dose of 10mg/kg one week after injection.)

Adalta expects to move into a Phase II study in the first half of 2024 with the IV version. This will be either in lung fibrosis (IPF), kidney fibrosis or eye fibrosis, with more preclinical data expected in the latter two which may direct the clinical program. The end point in lung fibrosis is a slowing of lung function decline, however according to CEO Tim Oldham, the rate of decline across patients is not linear (and therefore harder to measure the benefit). Measuring the effect on renal function is more predictable and consistent believes Oldham.

The Phase II study will likely recruit between 40 - 60 patients. Manufacture of product is scheduled to be completed by the end of 2023. The commercialisation of the inhaled version of AD-214 will be available for potential partners to in-license.

Adalta is capitalised at \$14 million with just \$9 million in cash at the end of September including the R&D tax rebate received this quarter.

**Bioshares recommendation: Speculative Buy Class B**

Bioshares

**How Bioshares Rates Stocks**

For the purpose of valuation, Bioshares divides biotech stocks into two categories. The first group are stocks with existing positive cash flows or close to producing positive cash flows. The second group are stocks without near term positive cash flows, history of losses, or at early stages of commercialisation. In this second group, which are essentially speculative propositions, Bioshares grades them according to relative risk within that group, to better reflect the very large spread of risk within those stocks. For both groups, the rating “Take Some Profits” means that investors may re-weight their holding by selling between 25%-75% of a stock.

**Group A**

Stocks with existing positive cash flows or close to producing positive cash flows

- Buy** CMP is 20% < Fair Value
- Accumulate** CMP is 10% < Fair Value
- Hold** Value = CMP
- Lighten** CMP is 10% > Fair Value
- Sell** CMP is 20% > Fair Value  
(CMP–Current Market Price)

**Group B**

Stocks without near term positive cash flows, history of losses, or at early stages of commercialisation.

**Speculative Buy – Class A**

These stocks will have more than one technology, product or investment in development, with perhaps those same technologies offering multiple opportunities. These features, coupled to the presence of alliances, partnerships and scientific advisory boards, indicate the stock is relative less risky than other biotech stocks.

**Speculative Buy – Class B**

These stocks may have more than one product or opportunity, and may even be close to market. However, they are likely to be lacking in several key areas. For example, their cash position is weak, or management or board may need strengthening.

**Speculative Buy – Class C**

These stocks generally have one product in development and lack many external validation features.

**Speculative Hold – Class A or B or C**

**Sell**

**Corporate Subscribers:** Cogstate, Opthea, ResApp Health, Pharmaxis, Dimerix, Adalta, Patrys, Antisense Therapeutics, Imugene, Chimeric Therapeutics, Neuren Pharmaceuticals, Neurotech International, Aroa Biosurgery, Radiopharm Theranostics, Imricor Medical Systems, Anteris Technologies

**Disclaimer:**

Information contained in this newsletter is not a complete analysis of every material fact respecting any company, industry or security. The opinions and estimates herein expressed represent the current judgement of the publisher and are subject to change. Blake Industry and Market Analysis Pty Ltd (BIMA) and any of their associates, officers or staff may have interests in securities referred to herein (Corporations Law s.849). Details contained herein have been prepared for general circulation and do not have regard to any person’s or company’s investment objectives, financial situation and particular needs. Accordingly, no recipients should rely on any recommendation (whether express or implied) contained in this document without consulting their investment adviser (Corporations Law s.851). The persons involved in or responsible for the preparation and publication of this report believe the information herein is accurate but no warranty of accuracy is given and persons seeking to rely on information provided herein should make their own independent enquiries. Details contained herein have been issued on the basis they are only for the particular person or company to whom they have been provided by Blake Industry and Market Analysis Pty Ltd. The Directors and/or associates declare interests in the following ASX Healthcare and Biotechnology sector securities: Analyst MP: ACR, AVR, CGS, CUV, CYC, DXB, IMM, LBT, MX1, OPT, NEU, PAB, PXS,RNO,SOM. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than \$100 are not disclosed.

**Subscription Rates (inc. GST)**

24 issues per year (electronic distribution): **\$550**

For multiple email distributions within \$900 2-3 email addresses  
 the same business cost centre, our \$1200 4-5 email addresses  
 pricing structure is as follows: \$1500 6-10 email addresses

To subscribe, post/email this subscription form to: **Bioshares**  
**PO Box 447 Flinders Lane Vic 8009**  
**editor@bioshares.com.au**

I enclose a cheque for \$ \_\_\_\_\_ made payable to **Blake Industry & Market Analysis Pty Ltd**, or

Please charge my credit card \$ \_\_\_\_\_ MasterCard  Visa

Card Number

Signature \_\_\_\_\_ Expiry date \_\_\_\_\_

**Subscriber details**

Name \_\_\_\_\_

Organisation \_\_\_\_\_

Ph ( ) \_\_\_\_\_

Emails \_\_\_\_\_

The information provided in Bioshares, including general investment advice, is provided only for receipt and use in Australia and New Zealand, for subscribers to Bioshares, who are Australian or New Zealand citizens or commercial entities.